MENS (Jyong Biotech) Shareholder Yield % : -16.36% (As of Dec. 2025)


MENS Jyong Biotech Ltd MENS
10 GF Score
Price $2.22
! 3 Warning Signs
View Full Analysis

What is Jyong Biotech Shareholder Yield %?

Jyong Biotech MENS +6.47% 10 Shareholder Yield % is -16.36% as of Dec. 2025. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 1,299 Biotechnology companies, Jyong Biotech ranks worse than 76.29% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Jyong Biotech's Shareholder Yield % was -16.36%.


Jyong Biotech  (NAS:MENS) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Jyong Biotech Shareholder Yield % Related Terms


Jyong Biotech Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Jyong Biotech's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jyong Biotech Shareholder Yield % Chart

Jyong Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
0.00 0.00 0.00 0.00 -9.17

Jyong Biotech Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shareholder Yield % Get a 7-Day Free Trial 0.00 0.00 0.00 -1.53 -9.17

MENS vs ENLV, CNTB, ACOG: Shareholder Yield % Comparison

For the Biotechnology subindustry, Jyong Biotech's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jyong Biotech Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jyong Biotech's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Jyong Biotech's Shareholder Yield % falls into.


MENS
10GF Score
Jyong Biotech Ltd MENS
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jyong Biotech Shareholder Yield % Calculation

Jyong Biotech's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-6.06 %+-3.11 %
=-9.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -16.36% mean?
Jyong Biotech (MENS) has a Shareholder Yield % of -16.36% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Jyong Biotech and its competitors. According to the industry distribution chart, Jyong Biotech ranks #991 out of 1299 companies in the Biotechnology industry, placing it in the top 76.3%.
Is Jyong Biotech's Shareholder Yield % too high?
Jyong Biotech's current Shareholder Yield % is -16.36%. Based on the distribution chart, Jyong Biotech ranks #991 out of 1299 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's Shareholder Yield % compare to ENLV and CNTB?
According to the Biotechnology industry distribution chart, Jyong Biotech ranks #991 out of 1299 companies for Shareholder Yield %. This places Jyong Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Jyong Biotech and its competitors. Jyong Biotech's current Shareholder Yield % is -16.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current Shareholder Yield % of -16.36%. The current Shareholder Yield % is -16.36%. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Jyong Biotech (MENS), the current Shareholder Yield % is -16.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jyong Biotech Business Description

Address Xintai 5th Road, 23F-3, No. 95, Section 1, Xizhi district, New Taipei, TWN, 221
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score

Get the complete analysis for MENS

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.22
Price